1-4 of 4
Jean-Pierre Cazenave, MD
Close
Sort by
Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4820.
https://doi.org/10.1182/blood.V122.21.4820.4820
Published: 2013
Journal Articles

Photochemical Pathogen Inactivation Treatment of Human Plasma (amotosalen + UVA) Has No Major Impact on the Protein expression pattern Assessed by a 2-DIGE Proteomic Assay.

Jean-Pierre Cazenave, MD, PhD, Philippe Ohlmann, Hervé Isola, Christian Gachet, MD
Journal: Blood
Blood (2008) 112 (11): 1994.
https://doi.org/10.1182/blood.V112.11.1994.1994
Published: 2008
Journal Articles

Inactivation of Infectious CMV in Platelet Products: Comparison of INTERCEPT Blood System™ and Leukofiltration.

John D. Roback, MD, PhD, Herve Isola, Lily Lin, PhD, Jean-Pierre Cazenave, MD
Journal: Blood
Blood (2007) 110 (11): 2886.
https://doi.org/10.1182/blood.V110.11.2886.2886
Published: 2007
Journal Articles

Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.

Jean-Pierre Cazenave, MD, PhD, Pierre Netzer, Simone Schuhler, Catherine Ravanat, PhD, Hervé Isola, Daniel Kientz, MD, Christian Gachet, MD, PhD, Marie-Louise Wiesel, MD
Journal: Blood
Blood (2007) 110 (11): 4027.
https://doi.org/10.1182/blood.V110.11.4027.4027
Published: 2007